1. Introduction {#sec1}
===============

Schizophrenia (SCZ) is a serious mental illness \[[@B1]\]. The World Health Organization estimates the global lifetime prevalence of SCZ at 3.8--8.4% \[[@B2]\]. SCZ is a severe psychosis induced by multiple factors and it manifests as a clinical syndrome with many symptoms. The course of the disease can include repeated relapses that aggravate disease and reduce quality of life. Some patients suffer from depression or mental disability \[[@B3]\]. Currently, clinical diagnosis of SCZ is based on the diagnostic scale of International Mental Disorders Classification \[[@B4]\]. The heterogeneous nature of SCZ pathogenesis has made it impossible so far to identify a single, reliable diagnostic biomarker or model.

Previous studies have shown that epigenetic changes may be related to the pathology of SCZ \[[@B5]\]. DNA methylation is the most stable epigenetic modification, and it can lead to changes in phenotype although the DNA sequence remains unchanged \[[@B6], [@B7]\]. DNA methylation may affect neuronal activity, transcriptional output, and synaptic function. Thus, methylation may be important in the pathology of SCZ \[[@B8]\]. Abnormal methylation of some genes, such as *DRD*2 \[[@B9]\], *DLGAP*2 \[[@B10]\], or *COMT* \[[@B11]\], may be associated with the occurrence and development of SCZ. In addition, a few DNA methylation-based classifiers for SCZ diagnosis have been reported \[[@B12], [@B13]\]. However, these studies were limited because they relied more on statistical associations without in-depth analysis of biological function.

In the present study, we identified common differentially methylated genes (CDMGs) shared across different brain regions in SCZ patients. We used the 10 CDMGs involved in the greatest number of neurological or psychiatric-related biological processes to construct a DNA methylation-based classifier for SCZ diagnosis. This method may be more biologically relevant than previous ones and may provide new insights to guide future research in SCZ.

2. Materials and Methods {#sec2}
========================

2.1. DNA Methylation in SCZ {#sec2.1}
---------------------------

In the present study, four SCZ methylation datasets (GSE89702, GSE89703, GSE89705, and GSE89706) were downloaded from the Gene Expression Omnibus database ([https://www.ncbi.nlm.nih.gov/geo/](https://www.ncbi.nlm.nih.gov/geo/))). DNA was isolated from postmortem brain samples. GSE89702 was derived from cerebellum from the Douglas Bell-Canada Brain Bank, and it included 16 SCZ samples and 17 normal controls. GSE89703 was derived from hippocampus, and it included 14 SCZ samples and 13 normal controls. GSE89705 was derived from striatum, and it included 16 SCZ samples and 17 normal controls. GSE89706 was derived from striatum from the London Brain Bank for Neurodegenerative Disorders, and it included 21 SCZ samples and 28 normal controls. The platform was GPL13534 and included each probe, the position on the chromosome, and the corresponding gene name of each probe. The normalized methylation data matrix was shown as beta values (ranging 0 to 1) of each probe with probe ID in row and patient ID in column. The workflow of the present study is shown in [Figure 1](#fig1){ref-type="fig"}.

2.2. Differential Methylation Analysis {#sec2.2}
--------------------------------------

Although GSE89705 and GSE89706 were both taken from the region of striatum, they were not combined because we did not know if there is any difference in the processing of samples between the two brain banks and that it is possible that combining datasets may result in some residual inflation according to a published study \[[@B14]\]. Thus, differential methylation analysis was performed separately in the four datasets using the limma package \[[@B15]\] in R software. The size of samples in each dataset was relatively small, and thus, the significance of differential methylation sites may be relatively low. If rigorously *P* value filtering, genes with potential biological function may be filtered out. Therefore, in the present study, differences with a *P* value \<0.05 were considered significant.

2.3. Enrichment Analysis {#sec2.3}
------------------------

To explore the biological functions of CDMGs that may be related to SCZ, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were performed using the ClusterProfiler package \[[@B16]\] in R. GO terms and KEGG pathways with *P* values \<0.05 were considered significant.

2.4. Variable Selection and LASSO Classifier {#sec2.4}
--------------------------------------------

Differentially methylated genes were involved in larger numbers of neurological or psychiatric-related biological processes and their methylation levels are thought to be more likely associated with SCZ than genes involved in fewer such processes. The differential methylation genes are different in different brain regions, and the differential methylation sites of the same gene in different brain regions may also be different. So we tried to build a brain-specific methylation-based classifier for SCZ. The corresponding different methylation sites of ten CDMGs involved in the most neurological or psychiatric-related biological processes were used to construct a diagnostic model of SCZ. These samples of the four datasets were randomly assigned to the training set (75%) and test set (25%), respectively. The four training sets were, respectively, used to select variables (different methylation sites) for establishing a DNA methylation-based classifier, and the test sets were used to validate the four classifiers. The glmnet package \[[@B17]\] in R used the least absolute shrinkage and selection operator (LASSO) \[[@B18]\] was used to select variables and construct a DNA methylation-based diagnostic classifier.

2.5. Evaluation of Methylation-Based SCZ Diagnostic Model {#sec2.5}
---------------------------------------------------------

The diagnostic performance of the DNA methylation-based SCZ diagnostic model was evaluated by accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUC) as analyzed in the pROC package \[[@B19]\] in R software.

3. Results {#sec3}
==========

3.1. SCZ-Related CDMGs in Different Brain Regions {#sec3.1}
-------------------------------------------------

We assessed DNA methylation characteristics from the four datasets taken from different regions of the brain. Compared with control groups from the respective datasets, we identified 7887 hypermethylated positions and 7484 hypomethylated positions in GSE89702 ([Figure 2(a)](#fig2){ref-type="fig"}), 5087 hypermethylated positions and 4227 hypomethylated positions in GSE89703 ([Figure 2(b)](#fig2){ref-type="fig"}), 5116 hypermethylated positions and 4275 hypomethylated positions in GSE89705 ([Figure 2(c)](#fig2){ref-type="fig"}), and 5569 hypermethylated positions and 4801 hypomethylated positions in GSE89706 ([Figure 2(d)](#fig2){ref-type="fig"}). A total of 849 genes were identified as CDMGs shared by all four datasets ([Figure 2(e)](#fig2){ref-type="fig"} and [](#supplementary-material-1){ref-type="supplementary-material"}). However, these CDMGs were methylated at different sites and to different degrees in different brain regions.

3.2. CDMGs Involved in Multiple Neurological or Psychiatric-Related Biological Processes and Pathways {#sec3.2}
-----------------------------------------------------------------------------------------------------

GO analysis of the SCZ-related CDMGs revealed these genes were involved in 244 biological processes, 43 cellular components, and 31 molecular functions (Figures [3(a)](#fig3){ref-type="fig"}--[3(d)](#fig3){ref-type="fig"}). KEGG pathway analysis showed that the CDMGs were involved in 80 signaling pathways, most significantly in PI3K-Akt, AMPK, and m-activated protein kinases/extracellular regulated protein kinases (MAPK/ERK), as well as several pathways related to neurological or psychiatric-related biological processes ([Figure 3(e)](#fig3){ref-type="fig"}). Notably, the CDMGs were involved in multiple neuronal axon-related biological processes ([](#supplementary-material-1){ref-type="supplementary-material"}); this suggests that the methylation level of CDMGs in neuronal axons may be associated with SCZ.

3.3. DNA Methylation-Based Diagnostic Model for SCZ {#sec3.3}
---------------------------------------------------

The following CDMGs were involved in the greatest numbers of neurological or psychiatric-related biological processes: SHANK3, WNT5A, NLGN1, GLI3, PTPRS, DISC1, SHH, BAIAP2, GLI2, and PAX6. The beta values of the differential methylation sites corresponding to these ten genes were used to construct a methylation template for diagnosing SCZ. Since our four datasets were taken from different regions of the brain, we found that these genes were differentially methylated based on their location---both in the brain region and on the DNA methylation position (Tables [1](#tab1){ref-type="table"}[](#tab2){ref-type="table"}[](#tab3){ref-type="table"}--[4](#tab4){ref-type="table"}). Therefore, the beta values of the differential methylation sites corresponding to each gene were collected, and the LASSO method was used for variable selection and construction of the DNA methylation-based classifier. The results suggested that the counts of differential methylation sites selected by LASSO in different brain regions were various ([Figure 4](#fig4){ref-type="fig"}). The diagnostic ability of the same CDMG in different brain regions varied, which indicated that the epigenetic dysregulation of SCZ is complicated.

3.4. Diagnostic Efficiency of the Composite Model in Training and Validation {#sec3.4}
----------------------------------------------------------------------------

In order to evaluate the diagnostic efficiency of the DNA methylation-based classifier, receiver operating characteristic curves were analyzed ([Figure 5](#fig5){ref-type="fig"}). In GES89702, GES89703, and GES89705, the accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and AUC in the training and test sets were 1 (Tables [5](#tab5){ref-type="table"}[](#tab6){ref-type="table"}--[7](#tab7){ref-type="table"}). In GES89706, the accuracy was 0.950 in the training set and 0.920 in the test set, while the AUC was 0.994 in the training set and 0.943 in the test set ([Table 8](#tab8){ref-type="table"}). The results suggest the DNA methylation-based classifier is a potential biomarker for diagnosing SCZ.

4. Discussion {#sec4}
=============

In recent years, the morbidity and mortality rates of SCZ have increased, and the many health- and social-related problems for patients with SCZ are cause for much concern. However, the effective molecular diagnostic methods are unmet. In particular, diagnostic models that take into account both the molecular statistical and biological significance have not received much attention.

In the present study, a total of 849 CDMGs were identified in different brain regions. Functional enrichment analysis indicated the CDMGs were involved in various neurological or psychiatric-related biological processes and pathways, specifically signaling pathways PI3K-Akt, AMPK, and MAPK. The methylation levels of CDMGs may affect these biological processes and pathways. Our study identified biological processes with confirmed roles in mental diseases, including SCZ \[[@B20], [@B21]\]. MAPK/ERK and PI3K/Akt signaling pathways can regulate protuberant growth and protein synthesis related to neural plasticity, and it can assist in the normal development of nerve cells, which may protect against SCZ \[[@B22]\]. The initiation of nerve axon regeneration is regulated by the MAPK pathway and this initiates a neuronal response \[[@B23]\]. Further studies should explore directly whether the CDMGs in the present study are associated with SCZ.

The beta values of the differential methylation sites corresponding to 10 CDMGs (*SHANK*3, *WNT*5*A*, *NLGN*1, *GLI*3, *PTPRS*, *DISC*1, *SHH*, *BAIAP*2, *GLI*2, and *PAX*6) which were most often involved in neurological or psychiatric-related biological processes were used to construct a DNA methylation-based brain region-specific for SCZ. The methylation sites within genes and degree of methylation varied in different brain regions, suggesting that the methylation patterns of SCZ-related genes are extremely complex. The DISC1 protein regulates the development, maturation, and migration of brain neurons and synaptic signal transmission \[[@B24]--[@B27]\], and disruption can lead to various mental diseases, including SCZ \[[@B28], [@B29]\]. The process of nerve development and synaptic transmission regulated by DISC1 can be affected by its degree of methylation \[[@B30]\]. *SHANK*3 knock out may affect neuronal development and induce SCZ \[[@B31]\]. *SHANK*3 and *NLGN*1 are also related to the progression of SCZ \[[@B32], [@B33]\]. However, few reports exist on the association of genes *WNT*5*A*, *GLI*3, *PTPRS*, *SHH*, *BAIAP*2, *GLI*2, or *PAX*6 with SCZ. Our results suggest that the methylation level of these genes may be related to the disease. Indeed, our DNA methylation-based classifier showed strong diagnostic potential based on AUC analysis. It is worth noting that due to the characteristics of LASSO method, the more the inclusion variables, the better the effect of the classifier. However, from the perspective of economics, the more the variables (differential methylation sites) are included, the higher the cost is. So taking into account the effectiveness of the model and the cost of economics, we started to perform feature section and classifier construction from 10 genes instead of fewer or more. From the results of the present results, when we included 10 genes, LASSO method identified differential methylation sites of 7-8 genes for us and obtained the best AUC value (close to 1). So we may foresee that the inclusion of fewer genes may greatly reduce classification efficiency, while the inclusion of more genes may be not necessary because it would increase costs but not increase the effect.

Some critical limitations exist in the present study. Due to the small sample size, our DNA methylation-based SCZ diagnostic model needs to be further validated and improved in larger, independent datasets. The potential roles of CDMGs in SCZ need to be explored experimentally.

Despite these limitations, our findings suggest that gene methylation patterns are significantly associated with SCZ and may be a promising diagnostic method. Methylation levels and sites in CDMGs varied widely across different brain regions, and future studies should explore the potential relevance of this variation for SCZ onset and progression.
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###### 

Table S1: common differential methylated genes in four datasets. Table S2: common differential methylated genes involved in neurological or psychiatric-related biological processes.

###### 

Click here for additional data file.

![Flowchart of the present study. Abbreviations: SCZ, schizophrenia; CDMGs, common differential methylated genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LASSO, least absolute shrinkage and selection operator.](BMRI2020-8047146.001){#fig1}

![Volcano plots of differentially methylated genes from each dataset. (a) GSE89702. (b) GSE89703. (c) GSE89705. (d) GSE89706. Red represents hypermethylation in SCZ relative to controls; blue, hypomethylation; and grey, no significant difference in methylation levels. (e) Venn diagram of differentially methylated genes amongst the four datasets.](BMRI2020-8047146.002){#fig2}

![Functional and pathway enrichment analysis of genes. CDMGs were involved in gene ontologies including (a) cellular components, (b) biological processes, and (c) molecular functions. (d) KEGG pathway analysis for CDMGs. (e) The CDMGs most significantly involved in 15 neurological or psychiatric-related biological processes.](BMRI2020-8047146.003){#fig3}

![Cross-validation (10-fold) for tuning parameter selection in the LASSO model in the four datasets. (a) GSE89702. (b) GSE89703. (c) GSE89705. (d) GSE89706.](BMRI2020-8047146.004){#fig4}

![Receiver operating characteristic curve analysis of the ability of our DNA methylation-based classifier to identify schizophrenia in the training set (left) and the test set (right) in the four datasets: (a) GSE89702. (b) GSE89703. (c) GSE89705. (d) GSE89706.](BMRI2020-8047146.005){#fig5}

###### 

DNA methylation sites in GSE89702 for constructing the SCZ diagnostic model.

  Probe ID     Genomic position            Gene           Gene region       *P* value   logFC
  ------------ --------------------------- -------------- ----------------- ----------- ---------
  cg09615965   chr3:55522560--55522836     WNT5A          TSS1500           0.049       --0.012
  cg09229620   chr3:122745183--122746986   NLGN1; NLGN1   5′UTR; 1st exon   0.048       0.038
  cg16216907   chr7:107220344--107221075   GLI3           5′UTR             0.014       --0.052
  cg10210571   chr1:231663999--231664608   TSNAX-DISC1    TSS200            0.039       --0.022
  cg20841191                               BAIAP2         Body              0.022       --0.031
  cg26475541   chr17:79026043--79026355    BAIAP2         Body              0.022       --0.028
  cg17454561   chr2:121745840--121746851   GLI2           Body              0.044       0.025
  cg13570972   chr11:31839363--31839813    PAX6           TSS200            0.034       --0.015

FC, fold change; TSS1500, transcription start site 1500; TSS200, transcription start site 200; 5′UTR, 5′ untranslated region.

###### 

DNA methylation sites in GSE89703 for constructing the SCZ diagnostic model.

  Probe ID     Genomic position            Gene           Gene region       *P* value   logFC
  ------------ --------------------------- -------------- ----------------- ----------- ---------
  cg09615965   chr3:55522560--55522836     WNT5A          TSS1500           0.049       --0.012
  cg09229620   chr3:122745183--122746986   NLGN1; NLGN1   5′UTR; 1st exon   0.048       0.038
  cg16216907   chr7:107220344--107221075   GLI3           5′UTR             0.014       --0.052
  cg10210571   chr1:231663999--231664608   TSNAX-DISC1    TSS200            0.039       --0.022
  cg20841191                               BAIAP2         Body              0.022       --0.031
  cg26475541   chr17:79026043--79026355    BAIAP2         Body              0.022       --0.028
  cg17454561   chr2:121745840--121746851   GLI2           Body              0.044       0.025
  cg13570972   chr11:31839363--31839813    PAX6           TSS200            0.034       --0.015

FC, fold change; TSS1500, transcription start site 1500; TSS200, transcription start site 200; 5′UTR, 5′ untranslated region.

###### 

DNA methylation sites in GSE89705 for constructing the SCZ diagnostic model.

  Probe ID     Genomic position            Gene     Gene region       *P* value   logFC
  ------------ --------------------------- -------- ----------------- ----------- ---------
  cg01777121   chr3:55517658--55517939     WNT5A    Body              0.044       0.028
  cg21904441                               NLGN1    Body              0.010       0.045
  cg02709068                               GLI3     Body              0.003       --0.029
  cg06213317   chr19:5250458--5250668      PTPRS    Body              0.017       --0.038
  cg27420590   chr19:5210564--5210864      PTPRS    3′UTR             0.023       --0.022
  cg23476745   chr17:79077317--79077518    BAIAP2   Body              0.043       --0.028
  cg23726427                               GLI2     Body              0.032       0.022
  cg26228577   chr2:121624827--121625209   GLI2     Body              0.010       --0.046
  cg05490712                               PAX6     5′UTR             0.031       --0.009
  cg18058532                               PAX6     5′UTR; 1st exon   0.041       0.007

FC, fold change; 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region.

###### 

DNA methylation sites in GSE89706 for constructing the SCZ diagnostic model.

  Probe ID     Genomic position            Gene          Gene region   *P* value   logFC
  ------------ --------------------------- ------------- ------------- ----------- ---------
  cg11676382   chr22:51142802--51143308    SHANK3        Body          0.031       --0.012
  cg06304401                               NLGN1         5′UTR         0.030       --0.007
  cg19510409                               NLGN1         Body          0.016       0.017
  cg15078211   chr7:42267546--42267823     GLI3          5′UTR         0.011       --0.014
  cg17390350   chr7:42267546--42267823     GLI3          5′UTR         0.002       --0.048
  cg22411165                               GLI3          Body          0.002       --0.020
  cg10518481   chr19:5339640--5341061      PTPRS         TSS1500       0.002       0.026
  cg04250837   chr1:231762414--231763115   TSNAX-DISC1   Body          0.041       0.019
  cg07007152   chr7:155601175--155603235   SHH           Body          0.014       0.015
  cg15244043   chr7:155604725--155605095   SHH           Body          0.007       0.011
  cg20521696   chr7:155601175--155603235   SHH           Body          0.029       0.030

FC, fold change; TSS1500, transcription start site 1500; 5′UTR, 5′ untranslated region.

###### 

Performance of DNA methylation-based classifier with GSE89702 data.

  Cohort         Se      Sp      PPV     NPV     Accuracy   AUC
  -------------- ------- ------- ------- ------- ---------- -------
  Training set   1.000   1.000   1.000   1.000   1.000      1.000
  Test set       1.000   1.000   1.000   1.000   1.000      1.000

Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating characteristic curve.

###### 

Performance of DNA methylation-based classifier with GSE89703 data.

  Cohort         Se      Sp      PPV     NPV     Accuracy   AUC
  -------------- ------- ------- ------- ------- ---------- -------
  Training set   1.000   1.000   1.000   1.000   1.000      1.000
  Test set       1.000   1.000   1.000   1.000   1.000      1.000

Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating characteristic curve.

###### 

Performance of DNA methylation-based classifier with GSE89705 data.

  Cohort         Se      Sp      PPV     NPV     Accuracy   AUC
  -------------- ------- ------- ------- ------- ---------- -------
  Training set   1.000   1.000   1.000   1.000   1.000      1.000
  Test set       1.000   1.000   1.000   1.000   1.000      1.000

Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating characteristic curve.

###### 

Performance of DNA methylation-based classifier with GSE89706 data.

  Cohort         Se      Sp      PPV     NPV     Accuracy   AUC
  -------------- ------- ------- ------- ------- ---------- -------
  Training set   0.890   0.900   1.000   0.900   0.950      0.994
  Test set       1.000   1.000   0.800   1.000   0.920      0.943

Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating characteristic curve.
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